- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
- ASSISTANT PROFESSOR | Otolaryngology
- Cancer (Oncology)
- Hospital Affiliation
- The Mount Sinai Hospital
- Ruttenberg Treatment Center 212-241-6756212-241-6756
- Adenoid Cystic Carcinoma (ACC)
- Cancer Prevention
- Head and Neck Cancers
- Laryngeal Cancer
- Lymph Node Biopsy
- Medical Oncology
- Mouth Cancer
- Nasal Cancer
- Nasal Cavity Cancer
- Nasopharyngeal Cancer (NPC)
- Needle Biopsy: Thyroid
- Oral Cavity Cancer
- Oropharynx Cancer
- Paranasal Sinus Cancer
- Pharynx Cancer
- Salivary Gland Tumors
- Salivary Glands
- Sinus Cancer
- Skull Base Tumor/Cancer
- Skull Base Tumors
- Squamous Cell Carcinoma
- Throat Cancer
- Thyroid Cancer
- Thyroid Tumors
- Tongue Cancer
- Tonsil Cancer
- Unknown Primary Tumors
Residency, Internal Medicine
St. Barnabas Medical Center
Mount Sinai Hospital
A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)
The purpose of this study is to test the safety, tolerability, and anti-tumor activity of an experimental drug called, pembrolizumab verses standard of care chemotherapies in subjects with recurrent and/or metastatic nasopharyngeal cancer. An experimental drug is not approv...
Phase I Study of Cabazitaxel- PF Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to collect information on the safety of Cabazitaxel and to learn how effective Cabazitaxel is in combination with Cisplatin and Fluorouracil in treating your type of cancer. Information from other research studies suggests that Cabazitaxel decreases t...
The goal of this research study is to compare the standard treatment to VTX-2337 added to the standard treatment to see if it helps your ...
A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
This study is divided into two parts: The purpose of the first part (phase Ib) of this study is to establish a safe dose range for BYL719 and cetuximab in combination, based on side effects. Once the right dose combination is found, the second part of the study will start. You wi...
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Misiukiewicz during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Eisai Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.